Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Biotechnology

Healthcare
$13.33 -1.34%

-$0.12 today

Market cap
$470.62M
Beta
1.08
P/E (TTM)
-36.3
EPS (TTM)
-$0.24
52W Low $5.65High $10.45

Volume 0.59M

Average 0.26M

FENC Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Fennec Pharmaceuticals Inc.NASDAQ: FENC

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 34.34M shares rose 24.5% year over year, ahead of the +10.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 10.1% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +24.5% holds above the trailing-twelve-month pace of +10.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
34.34M+10.1% QoQ
Last fiscal yearDec 2025
28.58M+4.7% YoY
LTMMar 2026
30.27M+10.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.5%——
1 year+4.7%——
3-year CAGR+2.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
28.58M USD
Year-over-year change
+4.7%
4-year CAGR
+2.4%

Weighted Avg Shares vs competitors

How FENC compares with its peers on the latest reported figures

  • FENC's LTM Mar 2026 weighted avg shares of 30.27M shares is the 7th highest of the 11 companies compared; the peer median is 41.45M shares.
  • Its year-over-year change of +10.4% is the 4th highest of 11, against a peer median of +1.9%.
  • Over three fiscal years its annual growth of +2.8% compares with a peer median of +15.8%.
FENC Competitors Peer median
Weighted Avg Shares for FENC and competitors
Company Period LTM YoY 3-year CAGR
NAUTNautilus Biotechnology, Inc.LTM Mar 2026126.35M +0.5%+0.4%
CRBUCaribou Biosciences, Inc.LTM Mar 202694.18M +3.6%+15.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 202656.95M +1.3%+16.2%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 202644.51M +24.9%+27.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202638.39M +2.6%+14.7%
FENCFennec Pharmaceuticals Inc.LTM Mar 202630.27M +10.4%+2.8%
RNACCartesian Therapeutics, Inc.LTM Mar 202626.2M +16.5%+86.2%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 202621.77M +1.1%+0.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202621.37M +0.6%+1.2%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +130.2%+599.3%
Peer median (excluding FENC) 41.45M+1.9%+15.8%

Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K250K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.19M33.05M41.88M47.22M
Depreciation & Amortization16K149K287K800K103K
EBITDA(17.22M)(22.59M)(12.36M)4.8M(7.45M)
EBITDA Margin—-1471.5%-58.2%10.1%-16.7%
Operating Income(17.22M)(22.74M)(13.06M)2.48M(6.35M)
Operating Margin—-1481.3%-61.4%5.2%-14.2%
Interest Income54K195K441K1.59M787K
Interest Expense126K978K3.39M4.07M2.08M
Other Income / Expenses(123K)(976K)(2.99M)(2.55M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense000365K106K
Net Income(17.35M)(23.71M)(16.05M)(436K)(9.74M)
Net Margin—-1544.9%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.95)(0.60)(0.02)(0.36)
EPS (Diluted)(0.67)(0.95)(0.60)(0.02)(0.36)
Weighted Avg Shares26.01M26.28M26.57M27.29M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.29M28.58M

Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Intrinsic Alpha fair value

Locked

Current Price

$13.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.